XOMA (NASDAQ:XOMA) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of XOMA (NASDAQ:XOMA - Free Report) from a hold rating to a buy rating in a research report report published on Friday morning.

Other equities research analysts have also issued reports about the company. Benchmark initiated coverage on XOMA in a report on Thursday, April 17th. They set a "buy" rating and a $35.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $104.00 price target on shares of XOMA in a report on Wednesday, May 28th.

XOMA Stock Down 2.2%

NASDAQ:XOMA traded down $0.54 on Friday, hitting $24.22. 19,412 shares of the company's stock traded hands, compared to its average volume of 31,050. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a 1 year low of $18.35 and a 1 year high of $35.00. The firm has a 50-day moving average price of $22.93 and a 200-day moving average price of $25.03. The company has a market cap of $289.84 million, a PE ratio of -6.96 and a beta of 0.89.

XOMA (NASDAQ:XOMA - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.32. The company had revenue of $15.91 million for the quarter, compared to analysts' expectations of $6.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. Equities analysts anticipate that XOMA will post -1.41 EPS for the current fiscal year.

Insider Buying and Selling

In other XOMA news, CIO Bradley Sitko purchased 4,134 shares of the business's stock in a transaction dated Friday, March 21st. The stock was bought at an average cost of $23.89 per share, for a total transaction of $98,761.26. Following the completion of the acquisition, the executive now directly owns 10,484 shares in the company, valued at $250,462.76. This represents a 65.10% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Owen Hughes sold 25,637 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $25.38, for a total value of $650,667.06. Following the transaction, the chief executive officer now owns 62,701 shares of the company's stock, valued at approximately $1,591,351.38. This trade represents a 29.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders purchased 29,312 shares of company stock worth $735,061. 9.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. GAMMA Investing LLC lifted its holdings in shares of XOMA by 1,063.8% during the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock worth $35,000 after buying an additional 1,585 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in shares of XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock worth $62,000 after buying an additional 800 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of XOMA by 38.0% during the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock worth $113,000 after buying an additional 1,183 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of XOMA by 5,087.9% during the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock worth $128,000 after buying an additional 6,309 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of XOMA by 34.7% during the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock worth $205,000 after buying an additional 2,009 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.